AMRI lands strategic deal with Knopp

- Last updated on GMT

AMRI lands strategic deal with Knopp
AMRI said it has entered into a strategic agreement with drug discovery firm Knopp Biosciences.

Under the two-year deal AMRI – which has worked with Kopp since 2006 - will provide various discovery-related services that include medicinal chemistry, DMPK and computer-aided drug discovery (CADD).

As part of the scope of work, AMRI scientists will collaborate with Knopp scientists and project leaders on selected novel drug discovery programs. The collaboration is extendable after two years by mutual agreement.

"We are pleased to expand our relationship with Knopp Biosciences, a company that values innovation through collaboration,​" said AMRI CEO, Thomas E. D'Ambra

He added that: "This agreement will combine AMRI's broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need​."

Related topics: Commercial Services, Preclinical

Related news

Show more

Related suppliers